Why Korro Bio, Inc.’s (KRRO) Stock Is Down 7.52%
As of Monday, July 13, Korro Bio, Inc.’s KRRO share price has dipped by 7.52%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Why Korro Bio, Inc.’s (KRRO) Stock Is Up 5.99%
As of Tuesday, July 07, Korro Bio, Inc.’s KRRO share price has surged by 5.99%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Korro Bio, Inc.’s (KRRO) Stock Is Up 6.36%
As of Monday, July 06, Korro Bio, Inc.’s KRRO share price has surged by 6.36%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Korro Bio, Inc.’s (KRRO) Stock Is Up 6.90%
As of Friday, June 26, Korro Bio, Inc.’s KRRO share price has surged by 6.90%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Korro Bio, Inc.’s (KRRO) Stock Is Down 11.18%
As of Thursday, June 25, Korro Bio, Inc.’s KRRO share price has dipped by 11.18%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | KRRO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $149.6 | $252.6 | 25% |
|
| Shares Out (Mil) | 11.6 | 52.3 | 23% |
|
| Institutional Ownership | 92.6% | 92.1% | 62% |
|
| Float (Mil) | 9.5 | 40.2 | 19% |
|
| Beta | 2.10 | 0.95 | 93% |
|
| Avg Daily Volume (000s) | 155 | 455 | 41% |
|
| Price Change (52-week) |
(36.2%) | 52.9% | 21% |
|
| Growth | KRRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 8 | |
| Current EPS | ($1.279) | ($5.179) | ($5.043) | |
| Month Ago EPS | ($1.279) | ($5.179) | ($5.043) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.824) | ($7.353) | ($7.593) | |
| Year/Year Chg | (24.4%) | (58.5%) | (59.6%) | |
| Financials | KRRO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $38 | 5% |
|
| Net Income (TTM) (Mil) | ($114) | ($43) | 10% |
|
| EPS (TTM) | ($11.408) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($70) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $5 | 37% |
|
| Long-Term Debt (Q1) (Mil) | $40 | $5 | 37% |
|
| Enterprise Value (Q1) (Mil) | $40 | $180 | 15% |
|
| Valuation | KRRO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.25 | 2.56 | 32% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KRRO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (58.8%) | (49.8%) | 10% |
|
| ROE | (87.8%) | (55.5%) | 11% |
|
| Liabilities to Assets | 34.8% | 30.3% | 26% |
|
| F-Score | 2 | 3 | 7% |
|
Korro Bio, Inc. did not pass any screens on 7/31/2026.
